Table 1 Patient demographics
From: A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors
N = 40 | |
|---|---|
Median age, years (range) | 38 (18–76) |
Gender (M/F) | 14 (35%)/26 (65%) |
Reason for inclusion: | |
Progression | 28 (70%) |
Pain | 26 (65%) |
Functional impairment | 20 (50%) |
Median time diagnosis to enrollment, | |
months (range) | 17 (1–187) |
Median previous relapses | 1 (0–10) |
Previous therapy: | 23 (57%) |
Previous surgery: | 21 (52%) |
More than 1 | 7 (17%) |
Previous radiotherapy: | 5 (12%) |
Previous chemotherapy: | 6 (15%) |
Location: | |
Thoracic wall | 10 (25%) |
Intraabdominal | 7 (17%) |
Upper extremity | 7 (17%) |
Lower extremity | 7 (17%) |
Head and neck | 6 (15%) |
Abdominal wall | 3 (7%) |
Location 2: | |
High risk (Head and neck | |
Or proximal Upper extremity) | 11 (27%) |
Other | 29 (72%) |
ECOG BASELINE: | |
0 | 15 (38%) |
1 | 24 (61%) |
Extension at baseline: | |
Localized | 18 (45%) |
Locally advanced | 22 (55%) |
Resectable baseline: | |
Resectable | 3 (7%) |
Unresectable | 37 (92%) |
Nuclear β-catenin expression | |
Positive | 39 (98%) |
Negative | 0 (0%) |
Not assessablea | 1 (2%) |
CTNNB1 mutation: | |
T41A | 22 (55%) |
S45F | 3 (8%) |
NA | 15 (37%) |
